|
|
 |
AWARENESS
LLS is a Partner in a
Thanksgiving Day TV Special to Raise Cancer
Awareness READ
MORE | |
 |
 |
PATIENT
SERVICES
Andrea Pitta, A Great Volunteer
in the San Diego/Hawaii Chapter READ
MORE
CMO Commentary: Chief
Medical Officer Barton Kamen, M.D., Ph.D., Talks
About AML
READ MORE
AML &
ALL Teleconferences in November
READ
MORE
Co-Pay Assistance Program
Broadens Funding READ
MORE | |
FUNDRAISING
UPDATES
Team In Training -
Featuring El Tour de Tucson and The Walt Disney
World Marathon and Half Marathon Weekend
READ MORE
Former Vice President
Al Gore was the Guest Speaker at San Francisco
Leukemia Cup Regatta
READ MORE
School & Youth -
LLS Presents Chairman's Citation Award to
Indianapolis Colts Gary Brackett, for His
Support of Pennies for
Patients
READ MORE
A Massachusetts
Chapter Hike Leader, Cellist Plans a 50-State
Tour to Benefit LLS
READ MORE
Cards for a Cause
Benefit LLS
READ MORE
Use Appreciated Stock
for Year-End Giving
READ MORE
RESEARCH
Chief Scientific
Officer Louis DeGennaro,
Ph.D., Participates in Conferences to
Advance Therapy Acceleration Program
READ MORE
Q&A - Pamela
Becker, M.D., Ph.D, of University of Washington
Discusses her Research Studying the Role of Cell
Adhesion in Chemotherapy Resistance
READ MORE
ADVOCACY
Senior Vice President
of Public Policy George Dahlman Elected Co-Chair
of Alliance for Childhood Cancer
READ MORE
FROM THE
LLS BLOG READ MORE
| |
|
|
|
 | | | | | |
|
|
|
Stars Take the Ice for
TV Special to Raise Cancer
Awareness
Olympic gold
medalist Scott Hamilton will skate on TV for the
first time since battling a brain tumor and
testicular cancer, joining fellow Olympian and
cancer survivor Dorothy Hamill for a
Thanksgiving Day special intended to inspire
viewers to triumph over illness.
The
Leukemia & Lymphoma Society (LLS) is one of
the advocacy partners of the program,
"Kaleidoscope," airing 4-5:30 p.m. EST Nov. 26
on Fox, along with 10 other organizations. The
opportunity to be part of this program was
brought to LLS by a researcher whose patient is
the executive producer of the show. The show is
designed to raise awareness and recognize the
role that women play in the battle against
cancer - as patients, caregivers and advocates.
The mission of this program is to address issues
surrounding women and cancer by helping educate
women to be proactive with their health and by
honoring all cancer survivors.
The
program will also will feature 1992 Olympic
figure skating champion Kristi Yamaguchi and
two-time medalist Nancy Kerrigan, along with
Olympic hopefuls Johnny Weir and Rachael Flatt.
Hamill, the 1976 gold medalist, will skate to a
song performed by Olivia Newton-John. Both women
were diagnosed with breast cancer.
"We're trying to get the word out in a
way that won't make people turn the channel the
second they hear the "C" word," says Hamilton,
winner of the 1984 Olympic gold medal and a
four-time world champion. "It's about embracing
life and moving forward and knowing you can get
back to your better self, your best self, even
after something as invasive and as challenging
as a cancer diagnosis and treatment."
Back to
the top
| | |
|
San
Diego-Hawaii Chapter Volunteer Wears Many Hats

Learning that you have cancer is
frightening and overwhelming. Patients and their
families need help to cope with the physical,
emotional and financial challenges that come
with a cancer diagnosis.
As a volunteer
patient navigation coordinator for the San
Diego-Hawaii Chapter of The Leukemia &
Lymphoma Society (LLS), Andrea Pitta, a
homemaker and mother of two, works with Patient
Services Manager Jose Montes, to identify
patients who need enhanced services, and helps
them get the support and resources they need to
make their way through the complicated journey
from diagnosis through treatment and
survivorship.
"It's a very
delicate process and I want to ensure that
patients know LLS is here to provide resources
to help make that aspect of their diagnosis a
little easier," says Pitta.
Pitta helped
create a welcome packet with disease-specific
information, along with information about local
services and upcoming events that might be
helpful for the patient.
But navigation coordinator is only
one of the many roles that Pitta plays as a
volunteer for the chapter. She also created an
innovative program for the chapter called
"Sophia's Hats," named after her grandmother,
Sophia May, who lost her 15-year battle with
leukemia in 2008. The program is completely run
by volunteers who create hats for patients who
have lost their hair from
chemotherapy.
"One morning after talking
with patients who had lost or were losing their
hair from treatment I thought it would be a
great idea to provide them with something to
make them look good and feel good about
themselves," Pitta said.
Pitta, who also
coordinates the chapter's annual Light The
Night® Walk
"Remembrance Ceremony," providing an opportunity
for family and friends to honor their loved ones
lost to a blood cancer, is one great example of
how to volunteer with LLS. Here is more
information about volunteering.
Back to the top

CMO Commentary: Acute
Myelogenous Leukemia: We Are Making
Progress!
Acute
Myelogenous Leukemia (AML) remains one of the
most difficult of the hematological
malignancies. For the past three decades, the
most widely used initial induction treatment for
AML patients has been a combination simply
referred to as "7 & 3." The protocol is
generally seven days of ARA-C (cytarabine) and
three days of an anthracycline, most often
daunorubicin, though there are several
variations on the dosages and durations. These
treatments often result in four to six weeks in
the hospital, and then yet more treatment.
At the end of September, two
articles and an editorial in the New England
Journal of Medicine suggested that some patients
would do better if they received twice the usual
dose of the daunorubicin. Not everyone would
benefit, such as those with adverse cytogenetics
or a mutation of the FLT3 gene. But the studies
showed that, at least in the short term,
toxicity was manageable so some patients could
benefit.
Why do I sound guardedly
optimistic that after 30 plus years we can
double the dose of a drug that was toxic and
possibly help some people? I do not think that
the treatment has really changed that much. The
supportive care (e.g. transfusion, antibiotics,
parenteral nutrition and intensive care units)
is better. My hopefulness relates to our
previous discussion of the 3 Ts of
treatment last month.
In this case the Typing is the
clue. When "7&3" was developed, all patients
diagnosed with AML were treated the same. Today,
if you are diagnosed with AML, we talk about
eight different classifications of the disease,
M0 through M7, based on the type of cell from
which the leukemia developed and how mature the
cells are.
Promyelocytic (M3) AML
has proven very susceptible to retinoic acid
(vitamin A) and arsenic Trioxide (yes a vitamin
and arsenic). Moreover, as we identify more
molecular biological/chromosomal changes we are
learning more about who will be more likely to
be cured and who will be resistant to treatment.
For example, patients with "Core Binding Factor"
(CBF) AML have a more promising prognosis,
whereas those with a mutation in FLT3 (FMS like
kinase) still pose more of a challenge to treat.
So what does this mean for
patients diagnosed with AML? With an overall
survival rate of 50%, AML remains one of the
more challenging hematologic malignancies.
However, for those with a "better prognosis"
AML, the standard therapy, perhaps now with a
double dose of the daunorubicin, might be all
that is required for the best risk benefit
ratio: the highest cure rate with minimal
toxicity. The lesson is that AML is very many
different diseases and patients need to be
treated at centers that are prepared to do all
the diagnostic tests in real time in order to
plan the optimal therapy. For many AML patients,
the standard of care remains a clinical trial
where novel protocols are being tested. A
clinical trial still affords the best path to
success in AML.
Information
for Newly Diagnosed Patients People
who have recently received a diagnosis of a
blood cancer often have questions about the
disease, the prognosis and the treatments
available. It is important to learn about
the disease, but also to learn about insurance
coverage, healthcare facilities and how to
obtain support. Specific questions may also be
answered by information specialists at The
Leukemia & Lymphoma Society's Information
Resource Center. The center
is open every business day, 9 a.m. to 6 p.m. ET,
at (800) 955-4572.
Additional Resources
on AML: Acute
Myelogenous Leukemia (AML) (PS32) Acute
Myelogenous Leukemia: A Guide for Patients and
Caregivers (PS66) Understanding
Clinical Trials for Blood Cancers (PS12)
The
Leukemia & Lymphoma Society Clinical Trial
Service -TrialCheck® Easily find
clinical trials near you through the
LLS-supported TrialCheck® website, a
clinical trial search service that offers
patients and caregivers immediate access to
listings of all leukemia, lymphoma and Myeloma
and related blood cancer clinical trials. Answer
just a few simple questions and a list of
available clinical trials related to your cancer
will appear in an easy to read list of search
results.
Back to the
top
Upcoming
Telephone/Webcast Education
Programs
The
Pediatric Treatment Approach to Adult Acute
Lymphocytic Leukemia: Perspectives for
Oncology Nurses
Date: Thursday,
November 19, 2009 Time:
12:00 PM to 1:30 PM Eastern Time
This nursing program will
feature Barton
A. Kamen, M.D., Ph.D., chief medical
officer of The Leukemia & Lymphoma Society,
Professor of Pediatrics and Pharmacology, The
Cancer Institute of New Jersey, UMDNJ - Robert
Wood Johnson Medical School, New Brunswick, NJ
and Katherine A.
Breitenbach, B.A., R.N., Clinical
Research Nurse Section of Hematology/Oncology,
University of Chicago Medical Center, Chicago.
This continuing education program is supported
by a grant from Enzon Pharmaceuticals,
Inc.
Understanding
AML: From Diagnosis to
Treatment
Date:
Tuesday, November 24, 2009 Time:
12:00-1:00pm Eastern Time
This program
will feature Elihu H.Estey,
M.D., Professor of Medicine, Division of
Hematology, University of Washington School of
Medicine, Member, Fred Hutchinson Cancer
Research Center Seattle, Adjunct Professor, The
University of Texas, M.D. Anderson Cancer Center
Houston. This continuing education program is
supported by a grant from Cephalon
Oncology.
NEW OPTION You now have the
option of listening to the program from your
computer (webcast). When you register for the
program, you will be asked if you want to
participate by phone or via webcast. If you
choose webcast, you will be sent an e-mail
providing you with a URL link for you to click
on the day of the program.
Featured Webclip
Program Financial
Health Matters
This program features interviews
with Anita
Welborn, LMSW of The Leukemia &
Lymphoma Society, Dana Krohn of
the Medicare Rights Center and David Landay,
Esq. of Survivorship A to Z and focuses on the
financial impact a cancer diagnosis can have,
with information on insurance programs and
resources for support. This
free educational
program is for patients,
caregivers and healthcare professionals. This is a complimentary online
continuing education activity.
Back to the
top
Co-Pay
Assistance Program Broadens
Funding Qualified
patients with chronic myelogenous leukemia and
myeloma can now receive up to $5,000 in
assistance from The Leukemia & Lymphoma
Society's (LLS) Co-Pay Assistance Program. The
aid helps offset prescription drug co-pays and
other insurance-related expenses according to
disease diagnosis. For more information, visit
www.LLS.org/copay or call (877) 557-2672.
The LLS Co-Pay Assistance program is pleased
to announce a new tool to help patients and
providers submit online applications quickly and
easily. The Co-Pay Assistance program provides
financial assistance for health insurance
payments and blood cancer treatment co-pay
obligations to qualified patients. For more
information, visit www.LLS.org/copay or call (877) 557-2672.
Back to
the top
| | |
|
Cycling in the Desert and a Trip
to the Magic Kingdom
Gene Espinosa, 47, of Tucson, has
overcome great odds to become a long-distance
cyclist. Espinosa was diagnosed in 1978 with
lymphoma at a time when there were few effective
treatments for the disease. Since that time,
researchers, many funded by The Leukemia &
Lymphoma Society (LLS), have advanced therapies
that have dramatically improved the survival
rates for this blood
cancer.
"Back then, the cancer was supposed to
kill you. If it didn't the chemicals usually
would," recalls Espinosa, who said he lost to
cancer many friends who he met during his stays
at the hospital. But Espinosa did survive. And
now he is dedicated to helping find cures for
patients with lymphoma and other blood cancers.
In 2005 Espinosa signed up for El Tour de
Tucson, a century ride in the Sonora Desert, as
a member of LLS's Team In Training (TNT). He has
participated in El Tour every year since then
and will be among approximately 300 TNT
participants taking part in this year's El Tour
de Tucson on November 21, 2009. Since 1996, TNT
has sent 7,200 participants to El Tour, raising
more than $18 million to support blood cancer
research and patient services.
Meanwhile, TNT participants are already
gearing up for another exciting event weekend at
the Walt Disney World Marathon January 9-10,
2010.
One of those participants is Megan
Lott, of Ft. Pierce, Fla., who ran the race last
year in honor of her cousin, Shana Pardue, a
lymphoma survivor, whose cancer was in
remission. Megan raised enough funds so
that both she and her cousin could be a part of
the LLS Palm Beach chapter team last year. This
season Lott has rejoined the team as an alumna,
but recently learned that her cousin's lymphoma
had returned. Pardue had begun training as a
member of Virtual TNT, but has had to put that
on hold because of the recurrence of her
lymphoma.
"Now I am more motivated than
ever to train and raise funds to support LLS's
mission," says Lott. In fact Lott has
joined the chapter's "Marathon Maniac" program
in which she will participate in all three
events offered by the chapter this winter, and
will raise over $5,000 in an effort to find a
cure.
TNT is currently recruiting for its
spring season, with events including the
Disney's Princess Half Marathon, the Mardi Gras
Marathon & 1/2 in New Orleans, and the
Marathon de Paris. To learn more please visit www.teamintraining.org.
Back to the
top
Greater San Francisco Leukemia
Cup Regatta Makes a Big
Splash
For the third year in a row, the Greater
San Francisco Chapter's Leukemia Cup Regatta
raised more than any other Leukemia Cup totaling
over $655,000 to
support blood cancer research and patient
services.
More than 100 boats, two days of
racing, and a fabulous VIP dinner, with special
guest former Vice President Al Gore, made for an
exciting weekend.
"We appreciate the support of
our honorary chairman, Tom Perkins. He
has been a key part of the Leukemia Cup for the
last three years, bringing his 88 meter yacht,
the Maltese Falcon, to San Francisco Bay for our
event and recruiting our last two keynote
speakers, Rupert Murdoch in 2008 and the
honorable Al Gore in 2009," said Bill Nolan, Bay
Area Chapter Trustee and Co-Chair. "Everyone
enjoyed Mr. Gore's discussion this year and, as
evidenced by the spirited response from our
audience, he made it a truly memorable
evening."
Bill Nolan was also the top San
Francisco fundraiser. His son, Campbell Nolan,
is a leukemia survivor. Bill was aboard the top
fundraising boat, Full Throttle, skippered by
committee co-chair David Joyner.
Co-Chair Ian
Charles was also on board.
More than a dozen participants -
Ian Charles,
Matt Cromar, Kyle Elliott, Erica Embley, Anne
Feinberg, David Joyner, Torin Knorr, John
McNeill, Suzie Moore, Bill Nolan, Molly Prahl,
Bill Smith, and Robin Reynolds qualified
for the Fantasy Sail with Leukemia Cup Regatta
National Chairman Gary Jobson
that took place at the San Francisco Yacht Club
October 17. Each of these qualifiers raised more
than $8,500 each totaling more than
$202,000! Click
here to learn more about the Leukemia Cup
Regatta.
Back to the
top
 LLS Recognizes Indianapolis Colts
Defensive Captain Gary
Brackett
In recognition of
his strong support for The Leukemia &
Lymphoma Society's (LLS) Pennies for
Patients®
program, the LLS Indiana Chapter last month
presented Indianapolis Colts defensive captain
Gary
Brackett with the Chairman's Citation
Award. Brackett accepted the award at a press
conference held at the Indiana Farm Bureau
Football Center.
"I'm thankful to
LLS, which is a great organization, for giving
me this award," Brackett said. "I think of
myself of being more than a football player. The
victories are great, but to really have lasting
impressions on your community and see some of
these kids and make an impact on their lives,
those are lifetime achievements."
Brackett's older brother, Greg, was
diagnosed with leukemia six years ago.
After finding out he was a match, Brackett
donated bone marrow to his brother, who
subsequently lost his battle to the disease in
2005. It is for this reason that Brackett
got involved with LLS three years
ago.
Brackett has been a "truly dedicated
supporter of LLS's Pennies for Patients,"
according to Indiana Chapter Executive Director
Amy Kwas. Brackett even made a personal visit to
the top two fundraising schools, both of which
collected more than $11,000 in
2009.
Nominations for the LLS Chairman's
Citation Award are made by local chapters and
presented in a local venue. The award recognizes
candidates who have made a significant impact in
the quest to find cures. Brackett joins an
illustrious group of other outstanding
professional athletes to have received the
award, including baseball greats Gary Carter,
Joe Mel Stottlemyre, Todd Stottlemyre and Frank
Thomas, and football stars Dan Marino, Bobby
Mitchell, Karl Nelson, Lawrence Taylor and Rod
Woodson.
Click
here to learn more about
Pennies for Patients, a school-based fund raiser
in which children collect spare change to
support blood cancer research and patient
services; and here, to learn about LLS's other School &
YouthSM
programs.
Back to
the top
50 Concerts in 50
States to Benefit LLS
A Boston-based
cellist, who has also led hikes for The Leukemia
& Lymphoma Society's (LLS) Team In Training
(TNT) program, has launched an ambitious
cross-country project to fight cancer by raising
funds and awareness state by
state.
Cellist Liam Abramson kicked off
his project, 50 Concerts in 50 States ( www.findacurenow.com), on Oct. 19 with a concert at the
Chicago Cultural Center. Abramson has set a goal
of donating at least $50,000 to LLS through the
24-month project.
Abramson, who
trained at the Royal College of Music in London
and is the recipient of numerous scholarships
and awards, has devoted his efforts to raising
money for cancer research since losing his best
friend to the disease in 2003. Abramson will
perform J.S Bach's Suites for Unaccompanied
Cello during this tour.
"I'm one of those
people who sets the bar high," said Abramson,
who has been a hike leader and mentor for TNT.
"The one piece of advice I consistently give out
is 'raise money by doing something you know how
to do.'"
Concerts are currently scheduled
for Ann Arbor, Mich. (Oct. 28, 2009); Boulder,
Colo.(Nov. 28, 2009); Sacramento, Calif. (Aug 7,
2010), Logan, Utah (2010), Searcy, Ark. (2010)
and Boston, Mass.(2010); Please visit www.findacurenow.com as the schedule will be continually
updated.
Back to the
top
"Cards for a Cause"
Benefits LLS
CardsDirect.com, a custom printed card and stationery
company, will be donating proceeds of the sale
of a special holiday card this season to The
Leukemia & Lymphoma Society (LLS) as part of
its "Cards for a Cause" holiday greeting cards
program.
CardsDirect launched 'Cards for a Cause'
holiday greeting cards program at the HBO
Luxury Lounge in honor of the 61st
Emmy Awards this year, where a line of exclusive
holiday greeting card designs were available for
celebrities to select. These cards will be on
sale on the CardsDirect website through December
31, 2009, with net proceeds from the sales of
these cards going to the celebrity's charity of
choice.
Jessica Lucas, a star of the show,
"Melrose Place," selected LLS.
You can
visit http://www.cardsdirect.com/cards-for-a-cause.aspx
, where the card that supports LLS
is featured. The card includes Lucas's printed
signature and charity logo along with your
custom imprinted verse and personalization, all
printed on 100% recycled card stock with 100%
post-consumer fiber.
Back to
the top
Use Stock Market
Gains For Charitable Giving
Recent stock market gains are
encouraging to some investors following last
year's price plunge. But many are more attuned
to market uncertainties than in the past and
want to protect their gains. One way you can
lock in the value of an investment is to use it
for year-end giving.
If you donate
appreciated shares that you have owned for a
year or more, you can claim a deduction for the
stock's full market value regardless of what you
actually paid for the investment. Further, you
will not owe any capital gains tax on the
appreciated amount.
For example,
Lotta Dough purchased stock for $1,000 a few
years ago. Today, her investment is worth
$5,000. If she donates the shares to The
Leukemia & Lymphoma Society, she is eligible
for a $5,000 charitable deduction and she avoids
$600 in capital gains tax that would have been
due on the increased value had she sold the
stock.
If you want to use
appreciated stock for your year-end giving,
request transfer instructions and our broker
information from Donor Relations: 1-888-773-9958
or click here.
Back to the
top
| | |
LLS
Therapy Acceleration Program Gains Industry
Attention
The Leukemia & Lymphoma Society's
(LLS) Therapy Acceleration Program (TAP)
continues to attract the attention of industry
leaders in drug development. LLS Chief
Scientific Officer Louis DeGennaro, Ph.D., has
been invited to several prestigious conferences
to participate as a panel member during the
month of October.
As a panelist for a
discussion entitled "Disease Foundations and
Venture Capital: Can the Two "Play in the Same
Sandbox?" hosted by MassBio on October 6,
DeGennaro joined six others, from Fast Forward,
LLC, an initiative to speed delivery of
treatment for patients with multiple sclerosis;
EMD Serono Inc., a biopharmaceutical company;
Juvenile Diabetes Research Foundation; Celetar
Pharmaceuticals and Tolerx, a biopharmaceutical
company.
The panel addressed ways that
disease foundations are investing and how
biotech companies are now collaborating with
both venture capital and foundations. It became
apparent that organizations like LLS conduct a
lot of diligence before deciding to fund a
company. The panel also addressed ways to work
with companies having difficulty achieving
critical development milestones. Ultimately the
panel concluded that biotech companies can in
fact satisfy investors with two different
endgames operating on two different timelines to
bring new therapies to patients.
On
October 28 and 29, DeGennaro will present LLS's
progress through TAP at the 8th
Annual Bio Investor Forum in San
Francisco. The forum will involve more than 110
late stage private and emerging public company
presentations, therapeutic panels led by
clinical thought leaders, and business
roundtables addressing key issues affecting drug
development in biotech companies.
"These
meetings provide LLS with a great opportunity to
talk about ways that we can build partnerships
with pharmaceutical and venture capitalists to
pool resources and develop drugs that can
further LLS's goal of bringing more treatments
to blood cancer patients more quickly," said
DeGennaro.
Founded in 2007, TAP supports
private sector and academic-based projects with
the goal of moving more blood cancer therapies
into the development pipeline. Click here to learn more.
Back to the
top
Research Q&A: Pamela S.
Becker, M.D., Ph.D.  Associate Professor of Medicine, Division
of Hematology University of Washington School
of Medicine . Recipient of a translational research
program grant from The Leukemia & Lymphoma
Society (LLS) to study cell adhesion mediated
chemotherapy resistance in acute myelogenous
leukemia and multiple myeloma
What is the
biomedical problem/issue that you are trying to
resolve? The focus of my research is
how adhesion to other cells within the bone
marrow enables acute myeloid leukemia cells to
resist chemotherapy. What's novel or
innovative about your approach? The
novel aspect of our approach is to determine the
critical interactions between leukemia stem
cells and leukemia-derived bone marrow stroma
(supportive cells), then utilize inhibitors of
this protective interaction to enhance
chemotherapy effect and leukemia cell death.
How will your work one
day help patients? Inhibitors of
adhesion are now being successfully combined
with chemotherapy agents in the lab to kill
leukemia cells better, and clinical trials are
being initiated to test this approach in
patients.
Are you close to
clinical trials? Yes, new clinical
trials are due to begin this fall, and early
trials are in progress.
What other projects
are you excited about and believe will benefit
patients? There may be potential for
new combinations of different agents that may be
more effective, and the potential for new drugs
as well.
What are some of your
hobbies and non-research interests?
My hobbies are gardening, swimming,
and music. I also volunteer for
LLS.
Back to
the top
| | |
The
Leukemia & Lymphoma Society Takes Leadership
Position on the Alliance for Childhood
Cancer
The Leukemia & Lymphoma Society (LLS)
has taken another step forward in its leadership
in the fight against pediatric cancer with the
unanimous election of LLS Senior Vice President
of Public Policy George Dahlman as the new
co-chair of the Alliance for Childhood
Cancer.
The
Alliance for Childhood Cancer represents more than twenty national
patient advocacy groups and
professional medical and scientific
organizations. Patient advocates, many of whom
are either cancer survivors themselves or are
parents of children with cancer, are joined by
oncology professionals and others representing
the multidisciplinary spectrum of cancer care in
a unique alliance that brings concerned parties
together to advance the interests of children
with cancer.
LLS policy goals mirror much
of the Alliance agenda and its leadership will
help focus collective attention on key
priorities for the pediatric cancer community.
Among them are:
- Pediatric
Cancer Research Funding: Last year
the Congress passed and the President signed
into law the Caroline Pryce Walker Conquer
Childhood Cancer Act, providing for enhanced
research, public education and a pediatric
cancer registry. Funding for the program is now
primary goal for the pediatric cancer
community.
- The
Childhood Cancer Survivorship Research and
Quality of Life Act (H.R.2109) was
introduced in the House of Representatives by
Jackie Speier (CA) Mary Bono Mack in April 2009.
This legislation would improve and enhance
cancer survivorship research and programs.
"This election is a great honor by
colleagues in the children's cancer family,"
said Dahlman, "It is my hope to fulfill their
confidence by bringing our collective weight to
bear in helping address the problems of children
with cancer and their
families."
Act
Now - Urge Your Representative to Co-Sponsor
Pediatric Cancer Survivorship
Legislation
Back to the
top
| | |
|
The Leukemia & Lymphoma
Society Blog is an interactive communication
resource, updated regularly with news from LLS,
as well as guest blog posts from those touched
by blood cancer. LLS welcomes your comments on
blog posts, as well as feedback to make this a
better communication resource for you.
Here's the latest from the LLS
blog:
Patient Story: Christen's little
miracle of hope
Back to
the
top
| | |
| | | |
|
|
 |
|
You are currently receiving
national news from LLS. Your
local chapter may also produce a local
eNewsletter called The Chapter
Report. If you'd like to receive
The Chapter Report please contact your
local chapter to subscribe.
Click here to
find your chapter's contact information.
|
Supported by an
unrestricted educational grant from  |
 |
|
eNEWSLINE is
published by The Leukemia & Lymphoma
Society® Home Office | 1311 Mamaroneck Avenue
| White Plains, NY
10605 914.949.5213 | www.LLS.org
© 2009 The Leukemia
& Lymphoma Society All Rights
Reserved
|
|
 |
| Participating member of An Alliance of
America's Premier Health Charities in the
Combined Federal Campaign, the National
Coalition for Cancer Research and Blood Cancer
Coalition. This publication is designed to
provide information in regard to the subject
matter covered, and is distributed as a public
service by The Leukemia & Lymphoma Society,
with the understanding that LLS is not engaged
in rendering medical or other professional
services.
The Leukemia &
Lymphoma Society® (LLS) is
the world's largest voluntary health agency
dedicated to blood cancer. The LLS mission: Cure
leukemia, lymphoma, Hodgkin's disease and
myeloma, and improve the quality of life of
patients and their families. LLS funds
lifesaving blood cancer research around the
world and provides free information and support
services.
Founded in 1949 and
headquartered in White Plains, NY, LLS has
chapters throughout the United States and
Canada. To learn more, visit www.LLS.org or
contact the Information Resource Center at (800)
955-4572, Monday through Friday, 9 a.m. to 6
p.m. ET. www.lls.org. |
 |
|
Visit our
e-Store
& Special Offers page,
where you can support businesses that support
LLS.
Please remember LLS in your will
or as a beneficiary in your retirement plan. For
information, call (888)
773-9958.
| | | | | |
|
| | | | |